Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
暂无分享，去创建一个
J. Burke | K. Kolibaba | I. Flinn | S. Kambhampati | D. Brander | N. Ghosh | S. Schuster | A. Mato | J. Chandler | F. Lansigan | J. Sharman | S. Lunin | M. Schreeder | P. Sportelli | M. Shtivelband | M. S. Weiss | H. Miskin | P. Travis | A. Zweibach | M. Weiss